Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data-Reference-Cited by-同舟云学术

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

Published:2015-04-19 Issue:1 Volume:170 Page:96-109
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bates Susan E.¹,Eisch Robin¹,Ling Alexander²,Rosing Douglas³,Turner Maria⁴,Pittaluga Stefania⁵,Prince H. Miles⁶,Kirschbaum Mark H.⁷,Allen Steven L.⁸,Zain Jasmine⁹,Geskin Larisa J.¹⁰,Joske David¹¹,Popplewell Leslie¹²,Cowen Edward W.⁴,Jaffe Elaine S.⁵,Nichols Jean¹³,Kennedy Sally¹⁴,Steinberg Seth M.¹⁵,Liewehr David J.¹⁵,Showe Louise C.¹⁶,Steakley Caryn¹⁷,Wright John¹⁸,Fojo Tito¹⁷,Litman Thomas¹⁹,Piekarz Richard L.¹⁸

Affiliation:

1. Developmental Therapeutics Branch; NCI; NIH; Bethesda MD USA

2. Department of Radiology; Warren G Magnuson Clinical Center; NIH; Bethesda MD USA

3. Consultative Cardiology; NHLBI; NIH; Bethesda MD USA

4. Dermatology Branch; NCI; Bethesda MD USA

5. Laboratory of Pathology; CCR; NCI; Bethesda MD USA

6. Peter MacCallum Cancer Centre; East Melbourne Vic. Australia

7. Hematological Malignancies; Penn State Hershey Medical Center; Hershey PA USA

8. Hofstra North Shore-LIJ School of Medicine and Monter Cancer Center; Lake Success NY USA

9. Columbia University; New York NY USA

10. Department of Dermatology; University of Pittsburgh Medical Center; Pittsburgh PA USA

11. Sir Charles Gairdner Hospital; Nedlands; WA Australia

12. City of Hope National Cancer Center; Duarte CA USA

13. Celgene Corporation; Cambridge MA USA

14. Independent Pharmaceutical Consultant; Boston MA USA

15. Biostatistics and Data Management; NCI; Bethesda MD USA

16. The Wistar Institute; Philadelphia PA USA

17. Center for Cancer Research; NCI; Bethesda MD USA

18. Cancer Therapy Evaluation Program; DCTDC; NCI; Bethesda MD USA

19. LEO Pharma A/S; Ballerup Denmark

Funder

National Cancer Institute

Celgene

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13400/fullpdf

Reference67 articles.

1. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma;Bates;British Journal of Haematology,2010

2. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells;Bhalla;Clinical Cancer Research,2009

3. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses;Bolden;Cell Death and Disease,2013

4. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin;Cabell;Blood (American Society of Hematology Annual Meeting Abstracts),2009

5. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors;Campbell;Blood,2010

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Romidepsin and afatinib abrogate JAK-STAT signaling and elicit synergistic antitumor effects in cutaneous T-cell lymphoma;Journal of Investigative Dermatology;2024-01

2. Clinical advances in epigenetic therapies for lymphoma;Clinical Epigenetics;2023-03-04

3. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities;Experimental Hematology & Oncology;2022-11-16

4. Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer;Cancers;2022-10-06

5. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma;Journal of Investigative Dermatology;2021-12